Traduction de «well as other equity » (Néerlandais → Français) :

Based on an evaluation of publicly available information about Alcon during the first half of 2009, no factors indicated that the “value in use” of this strategic investment to Novartis has fallen below the current carrying value of USD 136.84 per share (The revised carrying value from the previous level of USD 140.58 at the end of the first quarter of 2009 takes into account dividends paid in 2009 as well as other equity accounting adjustments).
Sur la base d’une évaluation des informations publiées sur Alcon au cours du premier semestre 2009, aucun facteur n’indiquait que pour Novartis, la valeur d’utilité de cet investissement stratégique était tombée en dessous de la valeur comptable d’USD 136,84 par action (cette valeur comptable inscrite au bilan et révisée par rapport à la valeur d’USD 140,58 à la fin du premier trimestre 2009, suite aux dividendes payés en 2009 ainsi que d’autres ajustements comptables résultant de l’application de la méthode de la mise en équivalence).

Full-year core income from associated companies rose 25% to USD 1.1 billion on increased underlying contributions from Roche as well as full-year equity accounting of the 25% Alcon stake after the mid-2008 purchase.
Le résultat «core» de l’exercice entier provenant des entreprises associées a progressé de 25% à USD 1,1 milliard grâce à une hausse des contributions sous-jacentes de Roche et à la première comptabilisation dans les capitaux propres de la participation de 25% dans Alcon sur un exercice entier après son acquisition à la mi-2008.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Financial debts and derivatives 5 660 5 186 474 8 741 Other current liabilities 8 966 7 923 1 043 8 311 Total current liabilities 17 902 16 504 1 398 19 954 Total liabilities 37 373 27 862 9 511 31 283 Total equity and liabilities 90 686 78 299 12 387 82 020
Dettes financières et instruments dérivés 5 660 5 186 474 8 741 Autres passifs courants 8 966 7 923 1 043 8 311 Total passifs courants 17 902 16 504 1 398 19 954 Total passifs courants et non courants 37 373 27 862 9 511 31 283

Other movements in equity were the net income of USD 7.7 billion, which was partially offset by the dividend payment for 2009 of USD 4.5 billion and actuarial losses of USD 1.4 billion.
Les autres mouvements relatifs aux fonds propres ont été le résultat net d’USD 7,7 milliards, qui a été en partie contrebalancé par le versement d’USD 4,5 milliards pour le dividende 2009 et par USD 1,4 milliard de pertes actuarielles.

Financial debts and derivatives 12 631 5 313 7 318 5 660 Other current liabilities 11 039 10 145 894 8 966 Total current liabilities 27 657 19 470 8 187 17 902 Total liabilities 58 410 38 043 20 367 37 373 Total equity and liabilities 124 628 95 505 29 123 90 686
Dettes financières et instruments financiers dérivés 12 631 5 313 7 318 5 660 Autres passifs courants 11 039 10 145 894 8 966 Total passifs courants 27 657 19 470 8 187 17 902 Total passifs courants et non courants 58 410 38 043 20 367 37 373 Total capitaux propres et passifs 124 628 95 505 29 123 90 686

Financial debts and derivatives 5 408 5 313 95 4 673 Other current liabilities 8 912 10 145 -1 233 7 365 Total current liabilities 17 829 19 470 -1 641 15 358 Total liabilities 41 108 38 043 3 065 33 786 Total equity and liabilities 96 924 95 505 1 419 84 274
Dettes financières et instruments financiers dérivés 5 408 5 313 95 4 673 Autres passifs courants 8 912 10 145 -1 233 7 365 Total passifs courants 17 829 19 470 -1 641 15 358 Total passifs courants et non courants 41 108 38 043 3 065 33 786 Total capitaux propres et passifs 96 924 95 505 1 419 84 274

Financial debts and derivatives 4 484 5 313 –829 4 474 Other current liabilities 9 387 10 145 –758 7 254 Total current liabilities 17 432 19 470 –2 038 14 990 Total liabilities 40 579 38 043 2 536 31 742 Total equity and liabilities 95 795 95 505 290 77 970
Dettes financières et instruments financiers dérivés 4 484 5 313 –829 4 474 Autres passifs courants 9 387 10 145 –758 7 254 Total passifs courants 17 432 19 470 –2 038 14 990 Total passifs courants et non courants 40 579 38 043 2 536 31 742

In Belgium, as in other countries, there are other energy drinks available which are often faithful copies of the original and which contain the same quantity of the three main ingredients, as well as other ingredients.
En Belgique, comme dans d’autres pays, d’autres boissons énergisantes coexistent, qui sont souvent des répliques fidèles de la boisson originelle et qui contiennent la même quantité des 3 composants principaux ainsi que d’autres composants.

This release contains forward-looking information that involves substantial risks and uncertainties concerning the possibility of future dividend increases. Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.
Such risks and uncertainties include, among other things, the Company’s future financial performance as well as general economic, political, business, industry, regulatory and market conditions.